





FIG. 2A

Myotube HiBit assay




DC_{50}

● Compound A

FIG. 2B

HEK293 high content assay



DC_{50}

FIG. 2C

Myotube HiBit assay






FIG. 2D

HEK293 high content assay








FIG. 4B




FIG. 4C

Nuclear AR clearance in myotubes




FIG. 5A




FIG. 5B




FIG. 6A





FIG. 6B






FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 8C





FIG. 8D







FIG. 8F


hAR100Q Tissue Cohort
Week 11
Quadriceps AR



65% reduction

FIG. 8G


hAR100Q Tissue Cohort
Week 11
Quadriceps hAR100Q



43% reduction

FIG. 8H

hAR100Q Tissue Cohort
Week 11
Quadriceps HMW hAR100Q






FIG. 9

FIG. 10





FIG. 11
SBMA hiPSC myotubes
Compound A






FIG. 12B
Compound A (active PROTAC)





FIG. 12C
Compound F (inactive PROTAC)






FIG. 13B
Cmpd A QDx3 DC50
LABC Total Drug
24hrs

